Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | MLYCD | O95822 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333428 | 0.85 | MAPK14 (0.66) | MAPK14ADORA2AADORA1ADORA2BMAPK9 | |
| SCHEMBL6090980 | 0.77 | MAPK14 (1.00) | MAPK14MAPK9MAPK10MAPK11MLYCD | |
| SCHEMBL6102776 | 0.77 | MAPK14 (1.00) | MAPK14MAPK9MAPK10MAPK11MLYCD | |
| SCHEMBL15452545 | 0.77 | MAPK14 (0.67) | MAPK14MAPK9MAPK10MAPK11LMNA | |
| SCHEMBL4329223 | 0.75 | MAPK14 (0.69) | MAPK14ADORA2AADORA2BMAPK9MAPK10 | |
| SCHEMBL4334618 | 0.73 | MAPK14 (0.66) | MAPK14ADORA2AADORA2BMAPK9MAPK10 | |
| SCHEMBL4330136 | 0.73 | MAPK14 (0.57) | MAPK14MAPK9MAPK10MAPK11LMNA | |
| SCHEMBL4333425 | 0.73 | MAPK14 (0.61) | MAPK14ADORA2AMAPK9MAPK10MAPK11 | |
| SCHEMBL1875864 | 0.73 | MAPK14 (0.66) | MAPK14MAPK9MAPK10MAPK11LMNA | |
| SCHEMBL17532580 | 0.73 | BRD4 (0.68) | MAPK14MAPK9MAPK10MAPK11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207203-B2 | Pyridylisoxazole derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090306145-A1 | Pyridylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2036905-A1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306145-A1 | Pyridylisoxazole Derivatives | CNKSR1, MAPK1, MAPK3 | MAPK14 43/4885ADORA2A 1351/4885ADORA1 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.